Multivariate analyses of the prognostic parameters used in the WHO 2022 classification demonstrated, within the restricted database of patients with stringent applicability of WHO and ICC, TP53 mutational status and multilineage dysplasia were independently associated with poor outcome. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.